Maduck Sean sold $2.0M of CORT
Maduck Sean sold 25,000 shares of CORCEPT THERAPEUTICS INC (CORT) at an average of $81.85 ($81.42–$82.68, $2.05M total) across 3 trades over 2026-11-02 to 2026-11-03 under a Rule 10b5-1 trading plan.
How this was made
The 30-second read
Why it matters
The disclosed sale reduces insider ownership and may be interpreted as a lack of confidence, prompting short sellers.
Market read
Insider sales are closely watched by traders; this filing provides fresh data that could affect short‑term price action.
What to watch
Potential upcoming clinical data releases that could offset the negative signal.
Background
Form 4 filing discloses insider transactions; such filings are primary sources for insider activity.
Ticker impact
Insider Maduck Sean sold 25,000 shares for $2.0M via a 10b5‑1 plan, reducing his stake to 9,938 shares.
likely slight downward pressure as the market prices in the insider sell
A $2M sale by an insider is material for a small‑cap biotech and often leads to short‑term price weakness.
Market effects
May raise caution for other small‑cap biotech stocks with recent insider sales.
Limited to U.S. markets; no broader regional effect.
Minimal global impact.
Counterpoint
The sale could be routine under a pre‑arranged plan and not reflect company fundamentals.
Key entities
- CompanyCorcept Therapeutics Inc
Biopharmaceutical company developing cortisol‑targeting therapies.
- InsiderMaduck Sean
Officer/director of Corcept Therapeutics who executed the sale.


